Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
7.09
+0.30 (4.42%)
At close: Aug 13, 2025, 4:00 PM
7.09
0.00 (0.00%)
After-hours: Aug 13, 2025, 4:10 PM EDT
Arvinas Employees
Arvinas had 430 employees as of December 31, 2024. The number of employees decreased by 15 or -3.37% compared to the previous year.
Employees
430
Change (1Y)
-15
Growth (1Y)
-3.37%
Revenue / Employee
$866,977
Profits / Employee
-$168,837
Market Cap
520.53M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARVN News
- 5 days ago - Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer - GlobeNewsWire
- 7 days ago - Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 14 days ago - Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 5 weeks ago - Arvinas Announces Retirement of Chief Executive Officer and Succession Plan - GlobeNewsWire
- 2 months ago - Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - GlobeNewsWire
- 2 months ago - Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer - GlobeNewsWire
- 2 months ago - Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting - GlobeNewsWire